Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.
The next frontier in medicine: drugs designed by artificial intelligence
More of Today's Solutions
How blocking one protein regenerates knee cartilage in aging mice and human t...
BY THE OPTIMIST DAILY EDITORIAL TEAM A Stanford Medicine study has identified a protein that roughly doubles in aging joints and blocks cartilage from ...
Read MoreHow heat domes form, intensify, and what they do to the body
BY THE OPTIMIST DAILY EDITORIAL TEAM More than 1,300 people die from extreme heat in the United States each year. The events behind the ...
Read MoreFeeling the gym blues? 7 strategies to kick your body comparison habit
You've prepared for that sizzling aerobic dancing class and are looking forward to crushing your workout. Unfortunately, the gym becomes an unanticipated battleground for ...
Read More3D-printed polypill covers all your medication for the entire day
Keeping track of many medicines and dosages might make it difficult to remember to take medication. However, a new invention in healthcare could provide ...
Read More
